Key facts
- AdipoPharma’s last known valuation is $18.4M.
- It has raised $34.5M; the latest was Later Stage VC ($9.4M) in Nov 2024.
- Notable investors include Bpifrance, Morningside Group, Good Growth Capital, Okeanos (United States), SambrInvest — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for AdipoPharma
- ·The full record, as it builds
Funding rounds
No funding rounds for AdipoPharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AdipoPharma
Developer of a peptide-based drug designed to offer treatment for patients suffering from type 2 diabetes. The company's drugs undergo a detailed analysis of the adipocyte's complex function, its intrinsic lipid modulating effects, and a targeted approach to treatment, enabling patients to restore healthy lipid biosynthesis in the diseased adipocyte and have a beneficial effect on insulin resistance as well as insulin sensitivity, beta-cell plaque removal, liver steatosis, and fibrosis.
- Sector
- Healthcare
- HQ
- Strasbourg, France
- Founded
- 2017
- Employees
- 6
- Website
- adipopharma.com/
- Ownership
- Privately Held (backing)
AdipoPharma doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AdipoPharma shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AdipoPharma in its N-PORT filings yet. We sweep new filings monthly.